[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
January 20, 2015

Antenatal Magnesium Sulfate and Outcomes for School-aged Children

Author Affiliations
  • 1Department of Neonatal Medicine, Rouen University Hospital and Région-INSERM (ERI 28), Normandy University, Rouen, France
  • 2Department of Biostatistics and INSERM UMR 657, Normandy University, Rouen, France

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(3):306. doi:10.1001/jama.2014.15912

To the Editor Based on extended follow-up of the randomized Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), Dr Doyle and colleagues1 reported that magnesium sulfate given to pregnant women at imminent risk of birth before 30 weeks’ gestation was not associated with neurological outcomes in school-aged children, although they could not exclude a mortality advantage. This report followed a Cochrane meta-analysis of 5 randomized trials including ACTOMgSO4 showing that magnesium sulfate reduced risks of cerebral palsy, general motor dysfunction, and combined death and cerebral palsy by age 2 years in very preterm children.2